Ventyx Biosciences Inc

Ventyx Biosciences — Technical Presentation (October 2023)

20 slides from Ventyx Biosciences's technical presentation, Oct 10, 2023

  1. Slide 1: VTX002 Phase 2 Ulcerative Colitis Results

    Exhibit 99.2 VTX002 Phase 2 Ulcerative Colitis Results October 9, 2023 1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Su

  3. Slide 3: Introduction

    Introduction Raju Mohan, Ph.D. Founder and Chief Executive Officer 3

  4. Slide 4: Speakers and Participants

    VTX002 Phase 2 Ulcerative Colitis Results Speakers and Participants Ventyx Management Team Guest Speaker and KOL Martin Auster, MD Chris Krueger, JD Raju Mohan, PhD William Sandborn, MD Bruce Sands, MD CHIEF EXECUTIVE OFFICER, PRESIDENT & CHIEF MEDICAL CHIEF FINANCIAL OFFICER CHIEF BUSINESS OFFICER

  5. Slide 5: William Sandborn, M.D. President and CMO

    VTX002 Phase 2 Ulcerative Colitis Results William Sandborn, M.D. President and CMO 5

  6. Slide 6: Executive Summary - Phase 2 Trial in Ulcerative Colitis

    Executive Summary - Phase 2 Trial in Ulcerative Colitis Data Establish VTX002 as a Potential Best-in-Disease Oral Agent Ø Potential best-in-disease oral efficacy and safety profile: § Highly differentiated efficacy on stringent and objective outcome measures § Compelling clinical remission rate § Un

  7. Slide 7: VTX002 Phase 2 UC Trial Design Overview

    VTX002 Phase 2 UC Trial Trial Design Overview Key eligibility criteria: Endpoints: • Patients with moderately to severely active UC as defined by • Primary Endpoint: Clinical remission at Week 13 as defined the Modified (3-component) Mayo Score by the Modified Mayo Score • Insufficient response, los

  8. Slide 8: Subject Disposition: High Trial Completion Rate

    Subject Disposition: High Trial Completion Rate Randomized and Treated (N=213)* Placebo (N=70) VTX002 30 mg (N=73) VTX002 60 mg (N=70) Discontinued treatment Discontinued treatment Discontinued treatment (N=3, 4.3%) (N=3, 4.1%) (N=4; 5.7%) Primary reason: Primary reason: Primary reason: Disease wors

  9. Slide 9: Baseline Demographics and Disease Characteristics

    Baseline Demographics and Disease Characteristics Placebo VTX002 30 mg VTX002 60 mg (N=70) (N=73) (N=70) Age, years, mean (SD) 40 (14) 42 (15) 39 (14) Female, n (%) 32 (46%) 26 (36%) 39 (56%) Geographic Region, n (%) North America 10 (14%) 16 (22%) 10 (14%) Europe 54 (77%) 53 (73%) 53 (76%) Other 6

  10. Slide 10: Compelling Clinical Remission and Endoscopic Improvement

    Compelling Clinical Remission and Endoscopic Improvement Primary and Secondary Endpoint at Week 13 vs. Placebo Placebo (N=70) Baseline MMS 5 to 9 (N=209) VTX002 30 mg (N=71) ∆ = 21% VTX002 60 mg (N=68) p=0.007 ∆ = 17% ∆ = 17% p=0.018 p=0.016 37% ∆ = 13% 32% p=0.041 28% 24% 16% 11% Placebo VTX002 VTX

  11. Slide 11: Unprecedented Rate of Complete Endoscopic Remission

    Unprecedented Rate of Complete Endoscopic Remission Secondary Endpoints at Week 13 vs. Placebo Placebo (N=70) Baseline MMS 5 to 9 (N=209) VTX002 30 mg (N=71) VTX002 60 mg (N=68) ∆ = 22% ∆ = 16% p=0.001 p=0.007 ∆ = 14% 29% ∆ = 10% p=0.014 p=0.046 22% 21% 16% 7% 6% Placebo VTX002 VTX002 Placebo VTX002

  12. Slide 12: VTX002 Is a Potential Best-in-Disease Oral Agent

    VTX002 Is a Potential Best-in-Disease Oral Agent S1P1 Modulator Competitive Landscape – Clinical Remission and Endoscopic Remission Placebo-Adjusted Clinical Remission Placebo-Adjusted Endoscopic Remission (ES=0) Phase 2 and Phase 3 Trials – Induction Period Phase 2 and Phase 3 Trials – Induction Pe

  13. Slide 13: Highly Competitive Clinical Remission Rate

    Highly Competitive Clinical Remission Rate Competitive Landscape – Absolute and Placebo-Adjusted Clinical Remission Clinical Remission (3 Component Mayo Score)* Phase 2 and Phase 3 Trials – Induction Period 33% 28% 27% 27% 26% 25% 23% 10% 18% 18% 17% 29% 17% 17% z 20% 15% 22% 25% 15% 10% 12% 12% 11%

  14. Slide 14: Unprecedented Rate of Complete Endoscopic Remission

    Unprecedented Rate of Complete Endoscopic Remission Competitive Landscape – Placebo-Adjusted Endoscopic Remission (ES=0) Placebo-Adjusted Endoscopic Remission (Endoscopic Subscore = 0) Phase 2 and Phase 3 Trials – Induction Period 22% Pooled rate = 15% 16% Pooled rate = 9% z 13% 12% 10% 10% Pooled r

  15. Slide 15: Unprecedented Rate of Complete Endoscopic Remission

    Unprecedented Rate of Complete Endoscopic Remission Competitive Landscape – Absolute and Placebo-Adjusted Endoscopic Remission (ES=0) Endoscopic Remission (Endoscopic Subscore = 0) Phase 2 and Phase 3 Trials – Induction Period 29% 18% 17% 22% 27% 26% 15% 15% z 14% 22% 22% 12% 9% 16% 10% 10% 7% 7% 13

  16. Slide 16: Pharmacodynamic Effect Is Consistent with Dose Response

    Pharmacodynamic Effect Is Consistent with Dose Response Absolute Lymphocyte Count (ALC) Percent Change from Baseline VTX002 30mg VTX002 60mg (N=71) (N=68) 0% • Rapid, robust and dose-dependent -10% reductions in absolute lymphocyte count (ALC) observed -20% -30% • VTX002 60 mg achieved a differentia

  17. Slide 17: VTX002 Was Safe and Well Tolerated: Summary of Adverse Events

    VTX002 Was Safe and Well Tolerated Summary of Adverse Events through Week 13 Placebo VTX002 30 mg VTX002 60 mg Treatment Emergent Adverse Events (N=70) (N=73) (N=70) Subject with any adverse event, n (%) 24 (34%) 34 (47%) 33 (47%) Adverse event related to study drug, n (%) 3 (4%) 7 (10%) 11 (16%) Ad

  18. Slide 18: VTX002 Was Safe and Well Tolerated: Adverse Events of Interest

    VTX002 Was Safe and Well Tolerated Adverse Events of Interest through Week 13 Placebo VTX002 30 mg VTX002 60 mg Adverse Events of Interest (N=70) (N=73) (N=70) Cardiovascular events, n (%) 3 (4%) 0 1 (1%) Hypertension 3 (4%) 0 1 (1%) Atrioventricular block 0 0 0 Bradycardia 0 0 0 Any severe infectio

  19. Slide 19: Conclusions from Phase 2 Trial in Ulcerative Colitis

    Conclusions from Phase 2 Trial in Ulcerative Colitis Phase 2 Data Establish VTX002 as a Potential Best-in-Disease Oral Agent Ø Potential best-in-disease oral efficacy and safety profile: § Highly differentiated efficacy on stringent and objective outcome measures § Compelling clinical remission rate

  20. Slide 20: Q&A Session

    Q&A Session Ventyx Management Team and Guest KOL Bruce Sands, MD CHIEF OF GASTROENTEROLOGY MOUNT SINAI HEALTH SYSTEM

Ventyx Biosciences — Technical Presentation (October 2023) on 6ix